<PubmedArticle xmlns:ns0="http://www.w3.org/1998/Math/MathML"><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39402977</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>31</Day></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Safety of an inactivated enterovirus 71 vaccine administered concurrently with other vaccines among infants aged 6-11 months: An observational study using active surveillance.</ArticleTitle><Pagination><StartPage>2412388</StartPage><MedlinePgn>2412388</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2412388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2024.2412388</ELocationID><Abstract><AbstractText>Vaccine co-administration can efficiently increase vaccination uptake and timely immunization. This study aimed to evaluate the safety of the enterovirus 71 (EV71) vaccine administered alone or concurrently with other vaccines in infants 6-11 months. A total of 3,769 EV71 vaccine doses were administered to children in the active surveillance area, of which 1,909 were administered concurrently with other vaccines and 1,860 doses were administered alone. Active surveillance was conducted to observe adverse events (AEs) within 0-7 and ≥8 days after vaccination and to determine the incidence of reported AEs. The overall AE incidence was 2.12% (95% CI: 1.66%-2.58%), with 1.56% (95% CI:1.00%-2.12%) for the EV71 vaccine alone and 2.67% (95% CI: 1.95%-3.40%) for simultaneous administration of the EV71 vaccine and other vaccines (<ns0:math><ns0:mrow><ns0:msup><ns0:mi>x</ns0:mi><ns0:mn>2</ns0:mn></ns0:msup></ns0:mrow></ns0:math> = 5.612, p = .018). The solicited local AE incidence was 1.00% (95% CI: 0.55%-1.44%) in the EV71 vaccine co-administration group and 0.59% (95% CI: 0.24%-0.94%) in the EV71 vaccine alone group (<ns0:math><ns0:mrow><ns0:msup><ns0:mi>x</ns0:mi><ns0:mn>2</ns0:mn></ns0:msup></ns0:mrow></ns0:math> = 1.946, p = .018). The solicited systemic AE incidence was 1.68% (95% CI: 1.10%-2.25%) and 0.86% (95% CI: 0.44%-1.28%) in the EV71 vaccine co-administered and EV71 vaccine alone groups, respectively (<ns0:math><ns0:mrow><ns0:msup><ns0:mi>x</ns0:mi><ns0:mn>2</ns0:mn></ns0:msup></ns0:mrow></ns0:math> = 4.990, p = .025). No serious vaccine-related AEs were reported. Fever was the most common AE; no difference was observed in the incidence rate of fever between the two groups (<ns0:math><ns0:mrow><ns0:msup><ns0:mi>x</ns0:mi><ns0:mn>2</ns0:mn></ns0:msup></ns0:mrow></ns0:math> = 3.467, p = .063). Overall, AE incidence following EV71 vaccination alone or concurrently with other vaccines was acceptable; concurrent vaccination did not increase AE risk or severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Linlin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jiechen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhuoying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Huiyong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaodong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Immunization Program, Shanghai Municipal Centers for Disease Prevention and Control, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Concurrent administration</Keyword><Keyword MajorTopicYN="N">EV71 vaccine</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>3</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39402977</ArticleId><ArticleId IdType="pmc">PMC11485911</ArticleId><ArticleId IdType="doi">10.1080/21645515.2024.2412388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koh WM, Badaruddin H, La H, Chen MI, Cook AR.. Severity and burden of hand, foot and mouth disease in Asia: a modelling study. BMJ Glob Health. 2018;3(1):e000442. doi:10.1136/bmjgh-2017-000442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2017-000442</ArticleId><ArticleId IdType="pmc">PMC5859810</ArticleId><ArticleId IdType="pubmed">29564154</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People’s Republic of China . Guidelines for the diagnosis and treatment of hand-foot-mouth disease (HFMD). 2018. www.nhc.gov.cn/yzygj/s3594q/201805/5db274d8697a41ea84e88eedd8bf8f63.shtml.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6513740</ArticleId><ArticleId IdType="pubmed">31156298</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Center for Disease Control and Prevention (CDC) . Technical guidelines for the use of inactivated enterovirus 71 vaccines. Beijing: Chinese CDC; 2016. https://www.chinacdc.cn/zxdt/201606/t20160608_131032.html.</Citation></Reference><Reference><Citation>Zhang J. [Trend of epidemics and variation of pathogens of hand, foot and mouth disease in China: a dynamic series analysis, 2008-2017]. Zhonghua Liu Xing Bing Xue Za Zhi. 2019;40(2):147–6. doi:10.3760/cma.j.issn.0254-6450.2019.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.0254-6450.2019.02.005</ArticleId><ArticleId IdType="pubmed">30744263</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KY. Enterovirus 71 infection and neurological complications. Korean J Pediatr. 2016;59(10):395–401. doi:10.3345/kjp.2016.59.10.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3345/kjp.2016.59.10.395</ArticleId><ArticleId IdType="pmc">PMC5099286</ArticleId><ArticleId IdType="pubmed">27826325</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Liu F, Liao Q, Wu P, Chang Z, Huang J, Long L, Luo L, Li Y, Leung GM, et al. Epidemiology of hand, foot and mouth disease in China, 2008 to 2015 prior to the introduction of EV-A71 vaccine. Euro Surveill. 2017;22(50):16–00824. doi:10.2807/1560-7917.ES.2017.22.50.16-00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.50.16-00824</ArticleId><ArticleId IdType="pmc">PMC5743100</ArticleId><ArticleId IdType="pubmed">29258646</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao QY, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15(5):599–606. doi:10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY. Enterovirus 71 infection and vaccines. Clin Exp Vaccin Res. 2017;6(1):4–14. doi:10.7774/cevr.2017.6.1.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.7774/cevr.2017.6.1.4</ArticleId><ArticleId IdType="pmc">PMC5292356</ArticleId><ArticleId IdType="pubmed">28168168</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828. doi:10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M, Meng F, Wang S, Li J, Zhang Y, Mao Q, Hu Y, Liu P, Shi N, Tao H, et al. 2-year efficacy, immunogenicity, and safety of Vigoo enterovirus 71 vaccine in healthy Chinese children: A randomized open-label study. J Infect Dis. 2017;215(1):56–63. doi:10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–837. doi:10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi L, Su K, Xia Y, Tang W, Shen T, Li Q. Enterovirus 71 vaccine acceptance among parents of children &lt; 5 years old and their knowledge of hand, foot and mouth disease, Chongqing, China, 2017. PLOS ONE. 2019;14(11):e0225569. doi:10.1371/journal.pone.0225569.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0225569</ArticleId><ArticleId IdType="pmc">PMC6881008</ArticleId><ArticleId IdType="pubmed">31774839</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Y, Shi L. A meta-analysis of the acceptance rate of EV71 vaccine among Chinese children’s parents in the east. J Trop Med. 2019;19:376–379.</Citation></Reference><Reference><Citation>Wang Y, Meng F, Li J, Li G, Hu J, Cao J, Yu Q, Liang Q, Zhu F. Willingness of parents to vaccinate their 6–60-month-old children with EV71 vaccines: A cross-sectional study in rural areas of northern Jiangsu Province. Vol. 16. Hum Vaccin Immunother; 2020. p. 1579–1585. doi:10.1080/21645515.2020.1737465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1737465</ArticleId><ArticleId IdType="pmc">PMC7482733</ArticleId><ArticleId IdType="pubmed">32209003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye L, Chen J, Fang T, Ma R, Wang J, Pan X, Dong H, Xu G. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China. BMC Public Health. 2021;21(1):1118. doi:10.1186/s12889-021-11198-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11198-6</ArticleId><ArticleId IdType="pmc">PMC8194148</ArticleId><ArticleId IdType="pubmed">34112128</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z, Liang Z, Zeng J, Zhang J, He P, Su J, Zeng Y, Fan R, Zhao D, Ma W, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, open-label, single-center, randomized, noninferiority trial. J Infect Dis. 2019;220(3):392–399. doi:10.1093/infdis/jiz129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiz129</ArticleId><ArticleId IdType="pubmed">30891604</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng QS, Sun RY. Lowest sample size and its safety in clinical trials in China. Chin J Clin Pharmacol Ther. 2003;8:354–355.</Citation></Reference><Reference><Citation>NMPA . The Guidelines for adverse event classification standards for clinical trials of preventive vaccines. https://english.nmpa.gov.cn/2019-12/31/c_448385.htm.</Citation></Reference><Reference><Citation>Liu XD, Chang SY, Wang RZ, Xiao YH, Li FJ, Xu Q, Zhang SB, Chen X, Zhang SX, Zhang M, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine administered simultaneously with hepatitis B virus vaccine, group A Meningococcal Polysaccharide Vaccine, measles-rubella combined vaccine and Japanese encephalitis vaccine: a multi-center, randomized, controlled clinical trial in China. Vaccines. 2022;10. Available from: 895.10.3390/vaccines10060895.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060895</ArticleId><ArticleId IdType="pmc">PMC9230521</ArticleId><ArticleId IdType="pubmed">35746502</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao YH, Guo X, Zhang M, Chen YP, Zhang YY, Yu XQ, Luo LY, Chen HP, Xu WC, Liu HB, et al. Safety and immunogenicity of enterovirus 71 vaccine (Vero Cell) administered simultaneously with trivalent split-virion influenza vaccine in infants aged 6–7 months: A phase 4, randomized, controlled trial. Vaccines. 2023;11(4):862. doi:10.3390/vaccines11040862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040862</ArticleId><ArticleId IdType="pmc">PMC10146551</ArticleId><ArticleId IdType="pubmed">37112774</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YP, Xiao YH, Ye Y, Jiang F, He HQ, Luo LY, Chen HP, Shi LB, Mu QY, Chen W, et al. Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China. Front Immunol. 2022;13:1080408. doi:10.3389/fimmu.2022.1080408.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1080408</ArticleId><ArticleId IdType="pmc">PMC9772018</ArticleId><ArticleId IdType="pubmed">36569946</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Global manual on surveillance of adverse events following
immunization. Available from: https://www.who.int/publications/i/item/9789241507769.</Citation></Reference><Reference><Citation>Tim S, Magnus N, Doug D, Magnus Y, Richard PH. A Structured Methodology to Assess Safety Signal Strength and Inform Causality Assessment. Pharm Med. 2022;36(4):215–222. doi:10.1007/s40290-022-00436-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40290-022-00436-w</ArticleId><ArticleId IdType="pmc">PMC9334375</ArticleId><ArticleId IdType="pubmed">35781676</ArticleId></ArticleIdList></Reference><Reference><Citation>Li ZQ, Qin ZQ, Tan HF, Zhang CH, Xu JX, Chen J, Ni LH, Yun C XX, Huang YM, Huang Y, et al. Analysis of the coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with the EV71 vaccine among children from 2016 to 2019 in Guangzhou. Expert Rev Vaccines. 2021;20(7):907–918. doi:10.1080/14760584.2021.1933451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1933451</ArticleId><ArticleId IdType="pubmed">34036862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang SQ, Hu Y, Liu K, Zhao MJ. Post-marketing safety surveillance of inactivated enterovirus 71 vaccine in Hubei Province, 2016–2017. Chin J Vaccines Immun. 2018;24:471–474. doi:10.1016/j.vaccine.2021.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.01.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayward S, Thompson LA, McEachern A. Is 13-valent Pneumococcal Conjugate Vaccine (PCV13) combined with 23-valent pneumococcal polysaccharide vaccine (PPSV23) superior to PPSV23 alone for reducing incidence or severity of pneumonia in older adults? A Clin-IQ. J Patient Cent Res Rev. 2016;3(2):111–115. doi:10.17294/2330-0698.1214.</Citation><ArticleIdList><ArticleId IdType="doi">10.17294/2330-0698.1214</ArticleId><ArticleId IdType="pmc">PMC4927079</ArticleId><ArticleId IdType="pubmed">27376105</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera L, Schwarz TF, Kim KH, Kim YK, Behre U, Cha SH, Jo DS, Lee J, Lee JS, Cheuvart B, et al. Immunogenicity and safety of the quadrivalent meningococcal vaccine MenACWY-TT co-administered with a combined diphtheria-tetanus-acellular pertussis vaccine versus their separate administration in adolescents and young adults: a phase III, randomized study. Vaccine. 2018;36(31):4750–4758. doi:10.1016/j.vaccine.2018.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.04.034</ArticleId><ArticleId IdType="pubmed">29960800</ArticleId></ArticleIdList></Reference><Reference><Citation>Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) administered concomitantly with a booster dose of a hexavalent vaccine in 12–23-month-old infants. Vaccine. 2015;33(20):2379–86. doi:10.1016/j.vaccine.2015.02.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.02.070</ArticleId><ArticleId IdType="pubmed">25765966</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanizzi P, Ferorelli D, Scazzi FL, DiLorenzo A, Martinelli A, Trinchera C, Moscara L, Miniello E, Di Bona D, Tafuri S. Allergic adverse events following immunization: Data from post-marketing surveillance in Apulia region (South of Italy). Front Immunol. 2023;14:1074246. doi:10.3389/fimmu.2023.1074246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1074246</ArticleId><ArticleId IdType="pmc">PMC10008905</ArticleId><ArticleId IdType="pubmed">36923411</ArticleId></ArticleIdList></Reference><Reference><Citation>Samit B, Amit V, Chirs TB. The impact of rare but severe vaccine adverse events on behaviour-disease dynamics: a network model. Nature. 2019;9(1):7164. doi:10.1038/s41598-019-43596-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-43596-7</ArticleId><ArticleId IdType="pmc">PMC6509123</ArticleId><ArticleId IdType="pubmed">31073195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>